Journal article · 2024 · Open access
Current therapeutics for Alzheimer’s disease and clinical trials
Exploration of neuroscience, 3(3), 255–271 · Published 27 June 2024 · DOI 10.37349/en.2024.00048
In brief
“Current therapeutics for Alzheimer’s disease and clinical trials” is a 2024 journal article by Danqing Xiao and Chen Zhang, published in Exploration of neuroscience. OpenAlex counts 35 citations as of 15 November 2026, which puts it in the top 7% of works published in 2024 by citations. It is open access under a CC BY licence: the full text is free to read at Exploration of neuroscience.
- Citations
- 35
- Most cited in
- 2026 (18)
- Field-weighted impact
- 4.70
- References
- 76
- Authors
- 2
Abstract
Alzheimer’s disease (AD) is a major type of dementia and neurodegenerative disease, characterized by memory loss and cognitive decline. Over decades, significant efforts have been dedicated to finding its cause, pathogenic mechanisms, biomarkers for early detection, and clinical trials for its treatment. Earlier approved drugs mainly ameliorated the symptoms of AD, until recent years when two drugs targeting amyloid-beta (Aβ) protein were approved to slow down the progression of the disease. This review article encompasses the history of drug development in treating AD and clinical trials that failed and succeeded. Clinicaltrials.org website was systematically searched and screened for randomized controlled trials with results posted in the past 10 years. Among the 3,388 AD clinical trials, 211 interventional studies registered under AD have met eligibility. This review includes the interventional targets for drug discovery such as Aβ, tau, neurotransmitter receptors, neuroinflammation, multi-target studies, repurposing pharmacological agents, non-pharmacological interventions, and clinical therapy development for the neuropsychiatric symptoms of dementia. Current clinical trials are ongoing and no results are available as of yet. With the vast choices of drug targets that have been investigated, this review aims to present some insights into future AD drug design and trials and contribute to our ongoing efforts to find the cure.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Xiao, D., & Zhang, C. (2024). Current therapeutics for Alzheimer’s disease and clinical trials. Exploration of neuroscience, 3(3), 255–271. https://doi.org/10.37349/en.2024.00048
MLA 9
Xiao, Danqing, and Chen Zhang. “Current therapeutics for Alzheimer’s disease and clinical trials.” Exploration of neuroscience, vol. 3, no. 3, 2024, pp. 255–271. https://doi.org/10.37349/en.2024.00048.
Chicago
Xiao, Danqing and Chen Zhang. 2024. “Current therapeutics for Alzheimer’s disease and clinical trials.” Exploration of neuroscience 3 (3): 255–271. https://doi.org/10.37349/en.2024.00048.
Harvard
Xiao, D. and Zhang, C. (2024) ‘Current therapeutics for Alzheimer’s disease and clinical trials’, Exploration of neuroscience, 3(3), pp. 255–271. doi:10.37349/en.2024.00048.
IEEE
D. Xiao and C. Zhang, “Current therapeutics for Alzheimer’s disease and clinical trials,” Exploration of neuroscience, vol. 3, no. 3, pp. 255–271, 2024, doi: 10.37349/en.2024.00048.
BibTeX
@article{xiao2024current,
title = {{Current therapeutics for Alzheimer’s disease and clinical trials}},
author = {Xiao, Danqing and Zhang, Chen},
journal = {Exploration of neuroscience},
year = {2024},
volume = {3},
number = {3},
pages = {255--271},
doi = {10.37349/en.2024.00048},
url = {https://doi.org/10.37349/en.2024.00048}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 2 | |
| 2025 | 15 | |
| 2026 | 18 |
Its field-weighted citation impact is 4.70: it has been cited 4.70 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- Alzheimer's disease therapeutics
- amyloid-beta
- tau protein
- therapeutic target
- drug repurposing
- neuroinflammation
- neurotransmitter receptors
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Xiao, D., & Zhang, C. (2024). Current therapeutics for Alzheimer’s disease and clinical trials. Exploration of neuroscience, 3(3), 255–271. https://doi.org/10.37349/en.2024.00048
How many times has this paper been cited?
35 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Exploration of neuroscience.
Who wrote this paper?
Danqing Xiao, Chen Zhang.
What is the DOI of this paper?
10.37349/en.2024.00048. The permanent link is https://doi.org/10.37349/en.2024.00048.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.